![Francis Darro](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Michel Allé | M | 74 |
Université Libre de Bruxelles
| 27 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Robert Kiss | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.
Université Libre de Bruxelles
| 15 Jahre |
Yvan de Launoit | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 12 Jahre |
Tanguy Cornet | M | - |
Université Libre de Bruxelles
| 5 Jahre |
Jean-Luc Samuel Francois Girardet | M | 57 |
Université de Montpellier
| 8 Jahre |
Piotr Tyranowski | M | - |
Université Libre de Bruxelles
| 4 Jahre |
Ugo Falcinelli | M | - |
Université Libre de Bruxelles
| 4 Jahre |
Alexey Viktorovich Lapikov | M | 48 |
Université de Montpellier
| 4 Jahre |
Tuan Van Nguyen | M | 54 |
Université Libre de Bruxelles
| 2 Jahre |
Stéphanie Vanden Broecke | F | - |
Université Libre de Bruxelles
| 3 Jahre |
Herjan Coelingh Bennink | M | - |
Université Libre de Bruxelles
| 8 Jahre |
Aminata Kaké | F | 47 |
Université Libre de Bruxelles
| 4 Jahre |
Nourredine Chinek | M | - |
Université Libre de Bruxelles
| 4 Jahre |
Frederic Halkin | M | - |
Université Libre de Bruxelles
| 1 Jahre |
Emmanuel Lacroix | M | - |
Université Libre de Bruxelles
| 4 Jahre |
Muriel de Lathouwer | F | 51 |
Université Libre de Bruxelles
| 4 Jahre |
Huong Giang Thi Luong | F | 57 |
Université Libre de Bruxelles
| 2 Jahre |
Benoît Taymans | M | - |
Université Libre de Bruxelles
| 4 Jahre |
Daniel Grossmann | M | 53 |
Université Libre de Bruxelles
| 5 Jahre |
Ayuporn Karnasuta | F | - |
Université Libre de Bruxelles
| 2 Jahre |
Alice Guilhon Lanfranchi | M | 57 |
Université de Montpellier
| 3 Jahre |
Gonzalo Tradacete Gallart | M | - |
Université Libre de Bruxelles
| 5 Jahre |
Ann J. Barbier | M | 59 |
Université Libre de Bruxelles
| 3 Jahre |
Bernd Karl-Friedrich Starrock | M | - |
Université de Montpellier
| 2 Jahre |
Bo I. Nilsson | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Steven D. Weitman | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Marc Hellemans | M | 51 |
Université Libre de Bruxelles
| 4 Jahre |
Alain Parthoens | M | 64 |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Kristel Verleyen | F | 53 |
Université Libre de Bruxelles
| 3 Jahre |
Amelie Coens | F | - |
Université Libre de Bruxelles
| 4 Jahre |
Dimitri Dimitriou | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Matthias de Raeymaeker | M | 49 |
Université Libre de Bruxelles
| 2 Jahre |
Antoine Duchateau | M | 70 |
Université Libre de Bruxelles
| 1 Jahre |
Keith Bragman | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Frédéric Zoller | M | - |
Université Libre de Bruxelles
| 4 Jahre |
Christiane Verhaegen | F | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 5 Jahre |
Didier Georges | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Sven Arne Andréasson | M | 72 |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Sandrine Evrard | F | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Mathieu Francois Pierre Pasture | M | - |
Université Libre de Bruxelles
| 1 Jahre |
Sandrine Gautier | M | - |
Université de Montpellier
| 3 Jahre |
Abderrezak Kamel | M | - |
Université de Montpellier
| 1 Jahre |
Etienne van de Kerckhove | M | 60 |
Université Libre de Bruxelles
| 1 Jahre |
Frank van Vynckt | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Eric van Quaquebeke | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 9 Jahre |
Marie Wintrebert-Fouquet | M | - |
Université de Montpellier
| 3 Jahre |
Didier Malherbe | M | - |
Unibioscreen SA
![]() Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Belgien | 40 | 85,11% |
Frankreich | 7 | 14,89% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Francis Darro
- Persönliches Netzwerk